Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

Following last week’s IPO market performance, which saw three biotechs raise more than $740 million, a trio of preclinical companies are now preparing for their at bat. The IPO queue also gained five more companies seeking NASDAQ listings on Friday, signaling a continued appetite for fresh biopharma paper.

Gene therapy company Generation Bio Co., vaccines play Vaxcyte Inc., and antibody-oligonucleotide conjugate company

Read the full 611 word article

How to gain access

Continue reading with a
two-week free trial.